<DOC>
	<DOCNO>NCT00152009</DOCNO>
	<brief_summary>The purpose study assess safety efficacy SPD503 ( Guanfacine hydrochloride ) compare placebo treatment ADHD child adolescent age 6-17</brief_summary>
	<brief_title>Safety Efficacy SPD503 Treating Attention-Deficit/Hyperactivity Disorder ( ADHD ) Children Aged 6-17</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Subjects primary diagnosis ADHD Male nonpregnant female subject agree comply applicable contraceptive requirement Subject current uncontrolled comorbid psychiatric diagnosis ( except ODD ) significant symptoms History seizure last 2 year Subject specific cardiac condition family history significant cardiac condition Subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>